Global Reach KCAS Bio operates across multiple US and European locations with a strategic alliance in Australia, enabling scalable global bioanalytical and biomarker services. Sales opportunities include multinational sponsor collaborations, cross-region project support, and streamlined regulatory submissions leveraging their proven FDA audit track record.

Proven Track Record With 45 years in bioanalytical drug development, support for over 315 approved drugs, and more than 20 FDA audits with no major findings, KCAS Bio presents a strong risk-mitigated choice for sponsors seeking reliable CRO partnerships and long-term engagements.

Diversified Services Capabilities span bioanalytical, biomarker, immunogenicity, cellular and molecular assays, plus clinical kitting and sample management. This breadth supports end-to-end programs, enabling sponsors to consolidate vendors and accelerate timelines.

Expansion & Events Frequent participation in major industry events (ESCGT, EBF, PharmaLab, BioFIT, ACT, AAPS, Immunogenicity Summit) signals active business development and opportunities to engage potential sponsors, showcase capabilities, and pursue new collaborations.

Financial Position Mid-sized CRO with estimated revenue in the short-mids range and a solid client base aligns KCAS Bio as a cost-effective partner for mid-size biotech and pharma programs seeking value, capacity, and stability without the scale risk of the largest CROs.